Loading
institutionsInstitution
Chinese Society of Clinical Oncology
China's clinical oncology society, whose annual meeting and disease guidelines are the reference for treatment in the world's largest cancer patient population.
Also called: CSCO中国临床肿瘤学会
Overview
Founded in 1997, CSCO is China's national society of clinical oncologists with tens of thousands of members and a large annual meeting each September that presents Chinese trial data on PD-1 antibodies, antibody-drug conjugates and targeted therapies. Its CSCO guidelines, published annually for each major cancer, grade recommendations by evidence and by accessibility in China and are the guidelines most Chinese oncologists use; they are increasingly cited internationally as Chinese drugs reach global markets. CSCO runs the CSCO Foundation for research grants, expert committees by disease, and a young oncologists' programme, and it holds joint sessions with ASCO, ESMO and JSMO. Its leadership includes the heads of the major Chinese cancer centres.
Location
Beijing, CN
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#329 · 20 points (0 Newsweek + 0 NCI + 20 from 10 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Chinese Society of Clinical Oncology, including child institutions. 1 works · 10 citations · 100% open access · 0% clinical trials · 0% reviews.
Oncology works per year
12022
02023
02024
02025
02026
Most works
- D. J. Park1 works
- Domenico D’Ugo1 works
- Francesco Roviello1 works
- W. Y. Lee1 works
- Gernard I. Chen1 works
- Douglas S. Tyler1 works
- Douglas B. Zippel1 works
- Haroon Javaid Majid1 works
- Isabel Teresa Rubio1 works
- Roland N. Auer1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Global Forum of Cancer Surgeons: Cancer Surgery During the COVID-19 Pandemic: Impact and Lessons Learned 10.1245/s10434-022-11506-3 · open access | Annals of Surgical Oncology | 2022 | 10 |
- CSCO Annual Meeting
- CSCO clinical guidelines (annual, by cancer)
- CSCO Foundation research grants
- Expert committees and international collaboration
Jun Guo
Professor; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital
MelanomaAcral and mucosal melanomaRenal cell carcinoma
Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.
Qing Zhou
Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
EGFR-mutant lung cancerBispecific antibodiesImmunotherapy
Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.
Shukui Qin
Professor of Medical Oncology; Nanjing Tianyinshan Hospital, China Pharmaceutical University (formerly Jinling Hospital, Nanjing)
Hepatocellular carcinomaGastrointestinal oncologyClinical trials
Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use.
Yi-Long Wu
Professor; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
Lung cancerEGFR-mutant NSCLCAdjuvant targeted therapy
Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.
Jin Li
Professor of Medical Oncology, Fudan University Shanghai Cancer Center and Shanghai East Hospital; gastrointestinal oncology
Colorectal cancerGastric cancerTargeted therapy
Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.
Rui-Hua Xu
President, Sun Yat-sen University Cancer Center; Professor of Medical Oncology
Gastrointestinal oncologyColorectal cancerOesophageal and gastric cancer
Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.
Similar pages
- InstitutionPeking University Cancer Hospital
Shares Jun Guo, CSCO guidelines (China), Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TrialHARMONi-2
Shares Qing Zhou, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
- Key paperHARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer
Shares Qing Zhou, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
- InstitutionInternational Association for the Study of Lung Cancer
Shares Yi-Long Wu, European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Immune checkpoint inhibitors.
- TrialA Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig
Shares Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialAK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor
Shares Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TrialCARES-310
Shares Shukui Qin, Hepatocellular carcinoma, Immune checkpoint inhibitors.
cancers
technologies
drugs
ApprovedBispecific antibody (PD-1×VEGF)
institutions
American Society of Clinical Oncology (ASCO)Cancer Hospital, Chinese Academy of Medical SciencesChina Anti-Cancer AssociationEuropean Society for Medical Oncology (ESMO)Fudan University Shanghai Cancer CenterNational Medical Products Administration / Center for Drug EvaluationSun Yat-sen University Cancer CenterWest China Hospital, Sichuan University